KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non-Current Assets (2018 - 2025)

Aurinia Pharmaceuticals' Other Non-Current Assets history spans 7 years, with the latest figure at $93000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 88.7% year-over-year to $93000.0; the TTM value through Dec 2025 reached $93000.0, down 88.7%, while the annual FY2025 figure was $93000.0, 88.7% down from the prior year.
  • Other Non-Current Assets reached $93000.0 in Q4 2025 per AUPH's latest filing, roughly flat from $93000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.3 million in Q4 2022 to a low of $93000.0 in Q2 2025.
  • Average Other Non-Current Assets over 5 years is $5.4 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: tumbled 94.09% in 2023, then skyrocketed 114.57% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $11.8 million in 2021, then increased by 12.68% to $13.3 million in 2022, then crashed by 88.63% to $1.5 million in 2023, then tumbled by 45.75% to $823000.0 in 2024, then plummeted by 88.7% to $93000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Other Non-Current Assets are $93000.0 (Q4 2025), $93000.0 (Q3 2025), and $93000.0 (Q2 2025).